Publications by authors named "Y Selim Ilhan"
Lung cancer is the leading cause of cancer-related death globally and is often diagnosed at an advanced stage. Nivolumab represents a significant advancement for treating advanced non-small cell lung cancer (NSCLC). However, the absence of reliable biomarkers predicting treatment response hinders personalized therapy.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness and safety of using granulocyte-colony stimulating factor (G-CSF) as a preventive treatment during chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
- A total of 119 patients were analyzed, comparing those who received G-CSF to those who did not, with results indicating better response and disease control rates in the G-CSF group, although the differences were not statistically significant.
- Overall, using G-CSF alongside the treatment protocol did not significantly improve efficacy or increase side effects, suggesting it can be safely integrated into treatment for ES-SCLC patients.